Manhattan Pharmaceutical (MHA)

[investorsster]

28,000 hits on google for a product coming on the market with a € 0,11 (!!) stockprice
$0,15 in no time
MANHATTAN PHARMACEUTICAL STOCK BEST BUY 2008

MANHATTAN PHARMACEUTICAL COMES WITH HEDRIN
PIPELINE:

Topical
PTH (1-34)
Psoriasis
Phase 1/2

----------

Altoderm™
Atopic
Dermatitis
(eczema)
Pruritus
Pre-IND (US)

----------

Hedrin™
Pre-IND (US)
------------------->NON TOXIC

(marketed in europe and the United Kingdom)

[investorsster]

On Nov 28, 2007 Manhattan Ph. Inc. announced the publication of POSITIVE clinical results for Hedrin(tm), the company's novel, non-insecticide product candidate for the treatment of head lice. These results appeared in the November issue of PLoS One, a leading international, peer-reviewed journal published by the Public Library of Science (PLoS).

The study findings demonstrate Hedrin's SUPERIOR EFFACY compared to malathion, a widely used insecticide treatment in both Europe and North America. In this randomized, controlled, assessor blinded, parallel group clinical trial, 73 adult and child subjects with active head lice infestations were treated with Hedrin or malathion liquid. Using intent-to-treat analysis, Hedrin achieved a statistically significant cure rate of 70% compared to 33% with malathion liquid. Using the per-protocol analysis Hedrin achieved a highly statistically significant cure rate of 77% compared to 35% with malathion. Additionally, Hedrin treated subjects experienced no irritant reactions, and Hedrin showed clinical equivalence to malathion in its ability to inhibit egg hatching. Overall, investigators and study subjects rated Hedrin as less odorous, easier to apply, and easier to wash out. Further, subjects treated with Hedrin stated they were significantly more inclined to use the product again (97%) versus those using malathion (31%).

"These findings are striking in that the data demonstrate such a dramatic increase in the head lice cure rate of Hedrin as compared to malathion," stated principal investigator, and head lice expert Ian Burgess, PhD, Director of Insect Research and Development Limited. "In addition to being shown to be a significantly more effective treatment alternative, Hedrin also appears to provide patients with key ease-of-use and lifestyle advantages over malathion. In their totality, these findings make a strong argument for Hedrin as a far superior head lice treatment option as compared to malathion."

To date, Hedrin has been clinically studied in 326 subjects and is currently marketed as a device in Western Europe and as a pharmaceutical in the United Kingdom (U.K.). In Europe, Hedrin has been launched in 21 countries and has achieved annual sales through its licensees of approximately $45 million at in-market public prices (which equates to a projected 21% market share), and is the market leader in the U.K. with $11 million in sales (23% market share) and France with a 21% market share. In the United States Manhattan Pharmaceuticals is planning to pursue a development pathway for Hedrin as a medical device, and will initiate that process in the fourth quarter of 2007. The company owns North American rights to Hedrin.

[Evolboarder]

Anyone keeping up with them anymore?

[gator16]

Check out svsn www.stereovision.com

[1000PERC]

thanks.. will check..

[gator16]

Yahoo message board has a bunch of good data on this

[gator16]

no problem

[1000PERC]

of course.. just wanted to get a quick opinion from the "only" poster on this mha board

[gator16]

My posts are my opinions ..do your own DD..you can call MHA investor relations as I have and get a quick update.

[gator16]

Very close to approval on obesity drug. Topical dermititus drug also has potential.

[gator16]

I think it has a run in it.Maybe 2 to 3 bucks

[1000PERC]

THINKING OF JUMPING IN.. HOW FAR OFF DO YOU THINK WE ARE BEFORE THIS THING ROCKETS?

[1000PERC]

FRIEND HERE AT WORK OWNS 50,000 SHARES.. WHAT DO YOU KNOW ABOUT MHA?? WAS THERE NEWS TODAY ON FIRSTCALL NEWS WIRE?

[gator16]

GO GATORS!!!!

[gator16]

This stock is getting ready to run and no one cares !!

[gator16]

96 cents and climbing !!!!!!

[gator16]

MHA starting to get noticed. Bout to hit a Home Run !! IMHO

[gator16]

If the 2A is a success this stock will rocket on spec alone..you are right..it won't be difficult to find money partners !! They are going thru heck at investor relations at this time but I think they will be okay in 5 months or less.

[trade1]

If the Phase II results are good then it won't be hard to partner. The markets to big for someone to not be interested in their obesity drug.

[gator16]

I own 16,200 shares and believe we have a real opportunity to make money here.
Do your own DD..this is just my opinion